Viromed Medical AG has received funding approval from the Federal Ministry of Research, Technology and Space for research and development projects in cold plasma technology, with the certification granted under the Research Allowance Act comprising funding in the high six-figure euro range. This financial support focuses on further developing innovative medical systems for applying cold atmospheric plasma, including a stationary system for integration into ventilation processes called PulmoPlas®. The technology aims to selectively inactivate pathogenic germs in the lower respiratory tract to enable new therapeutic approaches, particularly in intensive care medicine.
The funding also supports development of a mobile device for contact-free plasma application to support wound healing called ViroCap®. Both projects address key medical challenges and expand the current state of the art in medical technology. The application of cold plasma in the lungs represents a particularly novel approach for which no comparable systems currently exist, potentially offering new treatment options for respiratory infections that have become increasingly challenging to manage with traditional antibiotics.
This development matters because cold plasma technology offers a non-pharmacological approach to treating infectious diseases at a time when antibiotic resistance continues to grow as a global health threat. The technology works by generating a partially ionized gas at near-room temperature that can inactivate pathogens without damaging human tissue. For intensive care patients vulnerable to ventilator-associated pneumonia and other respiratory infections, this could represent a significant advancement in infection control and patient outcomes.
The funding underscores Viromed's innovative capabilities and confirms the scientific and technological relevance of its solutions. With this support, Viromed is advancing development of both PulmoPlas® and ViroCap® while strengthening its position in non-pharmacological treatment of infectious diseases. The company, which has been listed on the stock exchange since October 2022, focuses on distributing innovative cold plasma technology for medical applications through its wholly owned subsidiary Viromed Medical GmbH. More information about the company can be found at https://www.viromed-medical-ag.de.
The implications of this funding extend beyond the immediate development of specific devices. Successful implementation of cold plasma technology in medical settings could transform infection control protocols in hospitals, reduce reliance on antibiotics, and improve outcomes for patients with difficult-to-treat infections. For the medical technology industry, this represents continued innovation in physical antimicrobial approaches that complement pharmaceutical interventions. As healthcare systems worldwide grapple with antimicrobial resistance and hospital-acquired infections, technologies like those being developed by Viromed could become increasingly important components of comprehensive infection prevention and treatment strategies.
